health1 hour ago
AstraZeneca cites high placebo response for failed bone disease trial
AstraZeneca reported that its Phase 3 trial for an enzyme replacement therapy targeting hypophosphatasia, a rare genetic bone disease, failed to meet its primary endpoints. The company attributed the failure to a high placebo response, suggesting that the study design rather than the drug's efficacy was the primary issue. This setback follows recent Phase 3 misses for other AstraZeneca therapies, including its ATTR-CM silencer.